Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01856738 : Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease
PhasePhase 4
AgesMin: 40 Years Max: N/A
Inclusion Criteria:

- idiopathic PD with bradykinesia and at least two of the following signs; resting
tremor, rigidity, and asymmetry (in accordance with clinical diagnostic criteria of
the UK PD Society Brain Bank);

- the presence of minor VH for at least 4 weeks, defined by a score of 1 or 2 on the
hallucinations item of the Unified Parkinson's Disease rating Scale (UPDRS)1-MDS;

- age 40 years and over.

Exclusion Criteria:

- Parkinson's Disease Psychosis, defined as the need for antipsychotic drug treatment
in the opinion of the treating neurologist;

- Parkinson's Disease Dementia, defined by a score < 24 on the Mini Mental State
Examination (MMSE);

- current delirium (caused by infection or metabolic disturbance);

- current treatment with amantadine (Symmetrel) or anti-cholinergics, such as
trihexyfenidyl (Artane) or biperideen (Akineton);

- current or recent (<6 months) treatment with Cholinesterase inhibitor, such as
rivastigmine (Exelon) or galantamine (Reminyl);

- recent (<1 month) change in dopaminergic therapy;

- history of psychosis or severe ophtalmologic disease (e.g. Charles Bonnet syndrome);

- permanent stay in a nursing home;

- no informed consent.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557